In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...
News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results